OMERS ADMINISTRATION Corp Invests $1.42 Million in Hims & Hers Health, Inc. $HIMS

Key Points

• OMERS ADMINISTRATION Corp acquired 48,100 shares of Hims & Hers Health, Inc. valued at approximately $1,421,000 during the first quarter.
• CEO Andrew Dudum sold 660,000 shares for around $33.4 million, marking a significant 22.96% reduction in his ownership stake.
• Hims & Hers Health reported earnings of $0.17 per share, missing estimates, with revenue of $544.83 million, up 72.6% year-over-year.

OMERS ADMINISTRATION Corp bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 48,100 shares of the company's stock, valued at approximately $1,421,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $41,000. Larson Financial Group LLC increased its holdings in shares of Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares during the last quarter. Finally, Tsfg LLC acquired a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $46,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIMS. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Morgan Stanley reissued an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Up 8.5%

NYSE:HIMS traded up $3.79 during midday trading on Thursday, reaching $48.25. The company had a trading volume of 44,674,167 shares, compared to its average volume of 33,255,152. The firm has a market capitalization of $10.91 billion, a price-to-earnings ratio of 60.31, a PEG ratio of 2.86 and a beta of 2.14. The stock's fifty day simple moving average is $50.02 and its 200-day simple moving average is $45.56. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company's revenue for the quarter was up 72.6% on a year-over-year basis. During the same quarter last year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the sale, the chief financial officer directly owned 63,222 shares of the company's stock, valued at $2,987,239.50. The trade was a 26.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the sale, the insider directly owned 278,654 shares of the company's stock, valued at $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.